These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 32039250)

  • 21. Allogeneic adipose tissue-derived mesenchymal stem cells in combination with platelet rich plasma are safe and effective in the therapy of superficial digital flexor tendonitis in the horse.
    Ricco S; Renzi S; Del Bue M; Conti V; Merli E; Ramoni R; Lucarelli E; Gnudi G; Ferrari M; Grolli S
    Int J Immunopathol Pharmacol; 2013; 26(1 Suppl):61-8. PubMed ID: 24046950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinoic acid-mediated anti-inflammatory responses in equine immune cells stimulated by LPS and allogeneic mesenchymal stem cells.
    Abdelhamid L; Hussein H; Ghanem M; Eissa N
    Res Vet Sci; 2017 Oct; 114():225-232. PubMed ID: 28502902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().
    Carrade DD; Lame MW; Kent MS; Clark KC; Walker NJ; Borjesson DL
    Cell Med; 2012; 4(1):1-11. PubMed ID: 23152950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions.
    Carrade DD; Affolter VK; Outerbridge CA; Watson JL; Galuppo LD; Buerchler S; Kumar V; Walker NJ; Borjesson DL
    Cytotherapy; 2011 Nov; 13(10):1180-92. PubMed ID: 21899391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppressive properties of mesenchymal stem cells: advances and applications.
    De Miguel MP; Fuentes-Julián S; Blázquez-Martínez A; Pascual CY; Aller MA; Arias J; Arnalich-Montiel F
    Curr Mol Med; 2012 Jun; 12(5):574-91. PubMed ID: 22515979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro.
    Colbath AC; Dow SW; Phillips JN; McIlwraith CW; Goodrich LR
    Stem Cells Dev; 2017 Apr; 26(7):503-511. PubMed ID: 27958776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells.
    Pourgholaminejad A; Aghdami N; Baharvand H; Moazzeni SM
    Cytokine; 2016 Sep; 85():51-60. PubMed ID: 27288632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic Mesenchymal Stem Cell Therapy Promotes Osteoblastogenesis and Prevents Glucocorticoid-Induced Osteoporosis.
    Sui B; Hu C; Zhang X; Zhao P; He T; Zhou C; Qiu X; Chen N; Zhao X; Jin Y
    Stem Cells Transl Med; 2016 Sep; 5(9):1238-46. PubMed ID: 27365487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated intra-articular administration of equine allogeneic peripheral blood-derived mesenchymal stem cells does not induce a cellular and humoral immune response in horses.
    Van Hecke L; Magri C; Duchateau L; Beerts C; Geburek F; Suls M; Da Dalt L; Patruno M; Saunders J; Broeckx SY; Depuydt E; Spaas JH
    Vet Immunol Immunopathol; 2021 Sep; 239():110306. PubMed ID: 34365135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of genes involved in immune response and in vitro immunosuppressive effect of equine MSCs.
    Remacha AR; Barrachina L; Álvarez-Arguedas S; Ranera B; Romero A; Vázquez FJ; Zaragoza P; Yañez R; Martín-Burriel I; Rodellar C
    Vet Immunol Immunopathol; 2015 Jun; 165(3-4):107-18. PubMed ID: 25977164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.
    Berglund AK; Fisher MB; Cameron KA; Poole EJ; Schnabel LV
    Front Vet Sci; 2017; 4():84. PubMed ID: 28660198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization and osteogenic potential of equine muscle tissue- and periosteal tissue-derived mesenchymal stem cells in comparison with bone marrow- and adipose tissue-derived mesenchymal stem cells.
    Radtke CL; Nino-Fong R; Esparza Gonzalez BP; Stryhn H; McDuffee LA
    Am J Vet Res; 2013 May; 74(5):790-800. PubMed ID: 23627394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Procoagulant activity of human mesenchymal stem cells.
    Christy BA; Herzig MC; Montgomery RK; Delavan C; Bynum JA; Reddoch KM; Cap AP
    J Trauma Acute Care Surg; 2017 Jul; 83(1 Suppl 1):S164-S169. PubMed ID: 28628602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intra-Articular Injection of 2 Different Dosages of Autologous and Allogeneic Bone Marrow- and Umbilical Cord-Derived Mesenchymal Stem Cells Triggers a Variable Inflammatory Response of the Fetlock Joint on 12 Sound Experimental Horses.
    Bertoni L; Branly T; Jacquet S; Desancé M; Desquilbet L; Rivory P; Hartmann DJ; Denoix JM; Audigié F; Galéra P; Demoor M
    Stem Cells Int; 2019; 2019():9431894. PubMed ID: 31191689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton's jelly as sources of cell immunomodulatory therapy.
    Wang Q; Yang Q; Wang Z; Tong H; Ma L; Zhang Y; Shan F; Meng Y; Yuan Z
    Hum Vaccin Immunother; 2016; 12(1):85-96. PubMed ID: 26186552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.
    Kamm JL; Parlane NA; Riley CB; Gee EK; Dittmer KE; McIlwraith CW
    PLoS One; 2019; 14(11):e0225161. PubMed ID: 31747418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular Proliferation of Equine Bone Marrow- and Adipose Tissue-Derived Mesenchymal Stem Cells Decline With Increasing Donor Age.
    Bagge J; MacLeod JN; Berg LC
    Front Vet Sci; 2020; 7():602403. PubMed ID: 33363241
    [No Abstract]   [Full Text] [Related]  

  • 38. The effects of therapeutic concentrations of gentamicin, amikacin and hyaluronic acid on cultured bone marrow-derived equine mesenchymal stem cells.
    Bohannon LK; Owens SD; Walker NJ; Carrade DD; Galuppo LD; Borjesson DL
    Equine Vet J; 2013 Nov; 45(6):732-6. PubMed ID: 23448189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial.
    Sun Q; Huang Z; Han F; Zhao M; Cao R; Zhao D; Hong L; Na N; Li H; Miao B; Hu J; Meng F; Peng Y; Sun Q
    J Transl Med; 2018 Mar; 16(1):52. PubMed ID: 29514693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells.
    Naskou MC; Sumner SM; Chocallo A; Kemelmakher H; Thoresen M; Copland I; Galipeau J; Peroni JF
    Stem Cell Res Ther; 2018 Mar; 9(1):75. PubMed ID: 29566772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.